当前位置: X-MOL 学术Eur. J. Med. Chem. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Structure-based design of human immuno- and constitutive proteasomes inhibitors
European Journal of Medicinal Chemistry ( IF 6.0 ) Pub Date : 2018-01-08 , DOI: 10.1016/j.ejmech.2018.01.013
Nicolas Richy , Daad Sarraf , Xavier Maréchal , Naëla Janmamode , Rémy Le Guével , Emilie Genin , Michèle Reboud-Ravaux , Joëlle Vidal

Starting from the X-ray structure of our previous tripeptidic linear mimics of TMC-95A in complex with yeast 20S proteasome, we introduced new structural features to induce a differential inhibition between human constitutive and immunoproteasome 20S particles. Libraries of 24 tripeptidic and 6 dipeptidic derivatives were synthesized. The optimized preparation of 3-hydroxyoxindolyl alanine residues from tryptophan and their incorporation in peptides were described. Several potent inhibitors of human constitutive proteasome and immunoproteasome acting at the nanomolar level (IC50 = 7.1 nM against the chymotrypsin-like activity for the best inhibitor) were obtained. A cytotoxic effect at the submicromolar level was observed against 6 human cancer cell lines.



中文翻译:

人免疫和组成型蛋白酶体抑制剂的基于结构的设计

从我们先前的TMC-95A与酵母20S蛋白酶体复合的三肽线性模拟物的X射线结构开始我们引入了新的结构特征,以诱导人类组成型和免疫蛋白酶体20S颗粒之间的差异抑制。合成了24种三肽衍生物和6种二肽衍生物的文库。描述了从色氨酸的3-羟基氧代吲哚基丙氨酸残基的优化制备及其在肽中的掺入。获得了几种有效的人组成型蛋白酶体和免疫蛋白酶体抑制剂,它们的浓度为纳摩尔水平(IC 50 为最佳抑制剂的胰凝乳蛋白酶样活性,IC 50 = 7.1 nM)。观察到针对6种人类癌细胞系的亚微摩尔水平的细胞毒性作用。

更新日期:2018-01-08
down
wechat
bug